Rakovina Therapeutics Inc.
RKV.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.72M | 1.05M | 763.00K | 687.60K | 629.50K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.71M | 2.76M | 2.25M | 1.99M | 1.87M |
| Operating Income | -3.71M | -2.76M | -2.25M | -1.99M | -1.87M |
| Income Before Tax | -3.92M | -2.96M | -2.43M | -2.17M | -2.02M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.92 | -2.96 | -2.43 | -2.17 | -2.02 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.92M | -2.96M | -2.43M | -2.17M | -2.02M |
| EBIT | -3.71M | -2.76M | -2.25M | -1.99M | -1.87M |
| EBITDA | -3.33M | -2.36M | -1.85M | -1.59M | -1.47M |
| EPS Basic | -0.04 | -0.04 | -0.03 | -0.03 | -0.03 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| EPS Diluted | -0.04 | -0.04 | -0.03 | -0.03 | -0.03 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Average Basic Shares Outstanding | 401.37M | 330.68M | 300.37M | 280.51M | 279.61M |
| Average Diluted Shares Outstanding | 401.37M | 330.68M | 300.37M | 280.51M | 279.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |